Gainers
- Akanda AKAN shares increased by 13.5% to $0.63 during Tuesday's after-market session. Trading volume for this security closed at 668.1K, accounting for 276.8% of its average full-day volume over the last 100 days. The company's market cap stands at $2.4 million.
- VolitionRX VNRX shares moved upwards by 11.99% to $1.4. The company's market cap stands at $109.3 million.
- Virpax Pharmaceuticals VRPX shares moved upwards by 10.46% to $0.95. The market value of their outstanding shares is at $11.1 million.
- Cue Health HLTH stock moved upwards by 8.19% to $0.55. The market value of their outstanding shares is at $83.7 million.
- Longeveron Inc. - Subscription Right LGVNR shares increased by 7.49% to $0.04.
- AIM ImmunoTech AIM stock increased by 6.23% to $0.64. The company's market cap stands at $31.3 million.
Losers
- XBiotech XBIT stock fell 6.7% to $4.49 during Tuesday's after-market session. The market value of their outstanding shares is at $136.6 million.
- Carmell Therapeutics CTCX stock declined by 5.61% to $4.04. The company's market cap stands at $93.2 million.
- Novo Integrated Sciences NVOS stock fell 5.38% to $0.27. At the close, Novo Integrated Sciences's trading volume reached 20.9 million shares. This is 74.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $43.2 million.
- EyePoint Pharmaceuticals EYPT stock declined by 5.09% to $8.96. The market value of their outstanding shares is at $313.4 million.
- Orgenesis ORGS stock fell 5.08% to $0.71. The company's market cap stands at $21.6 million.
- Yield10 Bioscience YTEN shares decreased by 4.96% to $0.38. Today's trading volume for this security ended up closing at 243.6K shares, which is 86.0 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $4.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in